Abstract
Regarding chemoradiotherapy for head and neck cancers, evidence for the standard treatment is reported. When chemotherapy is used together, the use of single CDDP together is the standard. The JCOG head and neck cancer group was set up in recent years, and clinical trials to develop a standard regimen have begun. JCOG1008 is studying post-operative chemoradiotherapy for high-risk patients. JCOG1212 is studying super-selective intra-arterial chemoradiotherapy for maxillary sinus cancer. On the other hand, sometimes chemoradiotherapy is an unsuitable treatment due to its toxicity. It is also reported that patients cannot achieve long-term survival even if chemoradiotherapy is successful due to late toxicity. Long-term improvement of chemoradiotherapy results is expected by devising drug therapies such as using cetuximab in the future.
